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Context: Cushing Syndrome is difficult to diagnose, and the comorbidities and persistent late effects of
hypercortisolemia after treatment of the primary disease are challenging for the patient and the endocrinologist.
Objective: To report the case of a girl with obesity and hypertension, ultimately diagnosed with Cushing syndrome
due to primary pigmented nodular adrenocortical disease. In this case, the complications of hypercortisolism
persisted short term despite surgical intervention.
Patient: A 4 year old morbidly obese African-American girl with developmental delay presented with hypertensive
emergency in the ER and 18-month history of progressive weight gain. Her previous history included premature
adrenarche, hypertension, seizures and a random high cortisol with suppressed ACTH. She was subsequently
stabilized, and a diagnostic work-up persistently demonstrated elevated cortisol and suppressed ACTH. An
abdominal MRI showed bilateral adrenal multinodular disease, consistent with multinodular hyperplasia of the
adrenal glands. Based on these findings the patient underwent a bilateral adrenalectomy, which confirmed primary
pigmented nodular adrenocortical disease. The patient had a complicated, protracted post-operative course
requiring adjustment of therapy for persistent hypertension. Two months after surgery, she was readmitted to the
Emergency Department with hyperpyrexia and hypertension and succumbed to the complications of sepsis.
Conclusions and outcome: This case highlights the significant diagnostic and therapeutic challenges in treating
children with Cushing syndrome. Resolution of the source of hypercortisolemia does not imply regression of
hypertension or recovery of the immune system. Although the child underwent bilateral adrenalectomy, persistent
consequences of prolonged severe hypercortisolism contributed to her death two months later.
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Cushing syndrome, a syndrome of excessive cortisol circu-
lation, is a rare diagnosis in the pediatric population and
may arise from either endogenous secretion or exogenous
and iatrogenic administration of glucocorticoids [1].
Significant overlap of symptoms, such as weight gain,
hypertension, and glucose intolerance may occur, render-
ing the diagnosis difficult to establish, especially in the
case of mild symptoms [2–4]. The most common cause of* Correspondence: klinepet@bcm.edu
1Department of Pediatric Endocrinology and Metabolism, Texas Children’s
Hospital, Houston, TX, USA
Full list of author information is available at the end of the article
© 2015 Bartz et al. This is an Open Access arti
(http://creativecommons.org/licenses/by/4.0),
provided the original work is properly credited
creativecommons.org/publicdomain/zero/1.0/Cushing syndrome is administration of glucocorticoids,
which are being used more commonly in a wide range of
childhood diseases [5, 6]. Endogenous Cushing syndrome
is very rare, particularly in pediatric patients [4]. The two
major classifications of Cushing syndrome in pediatrics are
those with ACTH-independent and ACTH-dependent
causes, and the various etiologies appear to be somewhat
age-dependent [1, 7]. Of the ACTH-independent etiologies,
which account for 15 % of pediatric cases, the major ones
include exogenous steroid use, adrenocortical tumors, and
primary adrenocortical hyperplasia [1, 5]. Regardless of the
underlying cause, Cushing syndrome is arguably one of the
most complex endocrine conditions to diagnose [8]. Thecle distributed under the terms of the Creative Commons Attribution License
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quences even if the source of the hypercortisolemia is eradi-
cated. Cushing syndrome is also difficult to treat, and a full
cure with complete return to normalicy occurs infre-
quently. Herein, we present a unique case of a very young
child with primary pigmented nodular adrenocortical dis-
ease (PPNAD), resulting in Cushing syndrome and several




A 4 year, 4-month-old, morbidly obese, African-American
female with developmental delay and microcephaly pre-
sented to our Emergency Department (ED) with hyperten-
sive emergency.
Diagnosis evaluation
The inpatient endocrinology service was consulted for a
diagnostic work-up for Cushing Syndrome given a previ-
ous elevated cortisol value and cushingoid features. Her
rapid weight gain was documented in photographs pro-
vided by the family (Fig. 1). Physical examination revealed
poor growth (height of 98.2 cm, unchanged in 7 months,
Fig. 2), central obesity (weight, 40.6 kg; BMI >99th per-
centile, Fig. 2), moon facies, dorsocervical fat pad, and
prominent skin folds on all extremities. There was no
palpable glandular breast tissue. Striking violaceous striae
were present on the thighs and axilla. She did not have
any areas of increased skin pigmentation. Normal female
genitalia for age were identified. Sparse Tanner II pubic
hair extended from the labia to the pubis.
Further testing revealed a midnight salivary cortisol con-
centration of 0.341 ug/dl (normal, <0.010-0.090 ug/dl) and
two 24-hour free urinary cortisol concentrations of 67 ug/
d and 213.3 ug/d (normal, <18 ug/d). Serum cortisol and
ACTH concentrations were measured throughout the
day. Her serum cortisol was consistently elevated (range,
12–28.2 ug/dl) with no diurnal variation, and her ACTHFig. 1 Photographic progression demonstrating the dramatic weight gain
Just prior to presentation with her mother and c) At admission while in thewas consistently suppressed (<5 pg/ml). Her serum
11-deoxycortisol concentration was elevated at 661 ng/dl
(normal, 7–210 ng/dl), but she demonstrated normal con-
centrations of 17-hydroxyprogesterone, deoxycorticoster-
one, dehydroepiandrosterone, and dehydroepiandrosterone
sulfate. Serum androgens were borderline elevated, with
androstenedione of 65 ng/dl (normal 5–51 ng/dl) and tes-
tosterone of 10 ng/dl (normal <9 ng/dl).
Imaging studies obtained included an MRI of the brain
showing no increase in the adenohypophyseal size, and
no evidence of a pituitary adenoma. CT scan of the abdo-
men revealed diffusely thickened limbs of both adrenal
glands, with a nodular contour. MRI was performed in an
attempt to get a more discriminating view of the adrenal
glands. (Fig. 3). MRI again demonstrated uniformly thick-
ened adrenal glands with no evidence of an adenoma or
adreno-cortical carcinoma. A skeletal survey was negative
for fibrous dysplasia. Bilateral breast ultrasound and echo-
cardiogram were negative for myxomas and fibromas.
Management
Based on the combination of her physical examination,
laboratory evaluation, and imaging studies, a multidisciplin-
ary conference was held to discuss further intervention. A
diagnostic and therapeutic bilateral adrenalectomy was
scheduled 3 weeks into admission following completion of
antibiotic therapy for pneumonia, a urinary tract infection,
and subsequent culture-negative febrile episodes that oc-
curred during her hospitalization. Her laparoscopic adre-
nalectomy was converted to an open procedure secondary
to poor visualization and challenges of her body habitus.
Intraoperatively, she received her initial dose of glucocortic-
oid replacement therapy (100 mg of hydrocortisone).
Upon gross examination, the left adrenal gland weighed
4.1 grams and the right adrenal gland weighed 4 grams
(expected weight of combined adrenal glands 4.9 +/− 2
grams). Both adrenal glands demonstrated multiple
cortical-based, deeply red-brown pigmented nodules, with
intervening atrophic adrenal cortex (Fig. 4a). Microscopicof our patient over 18 months. a) 18 months prior to presentation, b)
ICU
Fig. 2 Height and Weight curve over 18 months for our patient, showing a dramatic increase in weight from the 95th percentile to well beyond,
yet a negligible height velocity
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showed features consistent with primary pigmented nodu-
lar adrenocortical disease (Fig. 4b). The adrenal glands
showed nodules with markedly enlarged cortical cells with
abundant eosinophilic cytoplasm and golden-brown pig-
ment, characteristic for PPNAD.
Our patient had a complicated, protracted postoperative
course. She remained hypertensive, requiring multidrug
therapy. She developed persistent fevers, despite receiving
broad-spectrum antibiotic coverage. She developed two
superficial surgical site infections, one requiring percutan-
eous drainage and the other incision and drainage with
negative pressure wound therapy. In addition, she devel-
oped an acute nonocclusive thrombus of the distal inferior
vena cava extending into the left common iliac vein, which
required long-term anticoagulation. After a prolonged
hospital course of 61 days, she was discharged home inFig. 3 a CT angiogram of the abdomen demonstrating thickened limbs of
glands. b Magnetic resonance imaging (MRI) of the abdomen confirmed th
dominant nodule to suggest adenoma or adrenal cortical carcinoma. Arrowstable condition with adrenal replacement therapy
(hydrocortisone 10 mg/m2/day and fludrocortisone
0.05 mg) and several antihypertensive medications (in-
cluding amlodipine, lisinopril, clonidine patch, and, as
needed, nifedipine).
One month after discharge and two months after sur-
gery, our patient returned to the ED quite edematous
with septic shock secondary to a life-threatening urinary
tract infection. The electronin medical records are not
clear concerning whether she received stress dosing of
steroids and a cortisol concentration was not obtained.
Blood and urine cultures subsequently returned positive
for Klebsiella pneumoniae and Enterococcus faecalis. She
succumbed to sepsis despite receiving aggressive treat-
ment and resuscitation in the ED 3 h after presentation.
An autopsy was not performed, at the request of her
parents.the adrenal glands with nodular contour. Arrows point to adrenal
e presence of thickened nodular adrenal glands with no evidence of a
s point to the two adrenal glands
Fig. 4 a Adrenal gland on cross sectioning shows several discrete, deeply red-brown nodules, consistent with PPNAD. b Golden brown pigment
with the cytoplasm of cortical cells from the adrenal gland are seen on microscopic examination, imparting the typical pigment seen on gross
examination with PPNAD (H&E stain, original magnification 400x)
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Our patient presented with glucocorticoid excess and a
variety of features including excessive weight gain and
decreased linear growth. Glucocorticoid excess can be
associated with decreased growth hormone (GH) secretion
[9], tissue resistance to IGF-1 [10], and decreased GH
response to stimulation testing [9, 10]. Bone age often is
delayed, as well [11]. The growth axis may be suppressed
for years after cure, leading to inadequate catch-up growth
and compromised final adult height, particularly in the
peripubertal child [9]. However, it was the hypertension
which brought our patient to seek medical attention which
eventually led to the diagnosis of PPNAD.
PPNAD is a rare genetic disorder with autonomously
functioning nodules that produce excessive cortisol [5].
The finding of these nodules with surrounding areas of
atrophy on microscopic examination is pathognomonic
for the disease [12]. The atrophy occurs because the au-
tonomous function of the nodules results in suppression
of ACTH secretion [1]. PPNAD often is seen in associ-
ation with Carney complex, a syndrome of multiple neo-
plasia of the endocrine gland, skin abnormalities, and
tumors. It was first described by J. Aidan Carney in 1985
in a case series of 40 patients [13, 5, 14]. Carney com-
plex is inherited in an autosomal dominant manner, with
very high penetrance [12]. The current diagnostic criteria
include skin lentigines, myxomas, and other endocrine and
nonendocrine tumors [15]. Generally, this disease occurs in
late adolescence or early adulthood, but a few case reports
describe it in younger children [7, 16]. Inactivating muta-
tions in the regulatory subunit of type 1 alpha of the protein
kinase A (PRKAR1A) gene have been identified in most of
the patients with PPNAD [1, 13]. Protein kinase A (PKA) is
the main mediator of cAMP signaling. PRKAR1A functions
as a tumor suppressor [13]. Forms of PPNAD without
manifestations or family history of Carney complex are rare.
Genetic studies were sent and negative for the PRKAR1Amutation. Our patient underwent whole exome sequen-
cing (WES), but a molecular diagnosis has not yet been
achieved.
Cushing syndrome is a progressive disease with multi-
system involvement. Treatment reverses, but may not
completely normalize, many of the deleterious effects of
hypercortisolism short term or long term [4]. Hyperten-
sion is a presenting feature in Cushing syndrome and
brought our patient to medical attention. The cause of
hypertension in Cushing syndrome is multifactorial and
includes priming of the vessels with glucocorticoids
so rendering catecholamines more effective [17], salt-
retention from high cortisol state, and variable renin-
angiotensin system activation [18]. Hypertension reshapes
the cardiovascular system, which does not appear to re-
turn to normal, and a permanent loss of vessel elasticity
is reported in adults [18]. Data on the long-term out-
comes of hypertension are lacking, but some reports
indicate blood pressure may not completely normalize
[19, 20]. In a review of 113 children with Cushing syn-
drome, blood pressure normalized in most by one year
after cure, but a portion remained hypertensive [21].
Although we have only two months of post-operative
data on our patient, her hypertension persisted post-
operatively and the patient required multidrug therapy
for this comorbiditiy.
In Cushing syndrome, another potential insult to the
cardiovascular system is the increased risk of venous
thromboembolism (VTE) [22–24]. This increased hyper-
coagulability appears to be especially problematic after
surgery or during active disease [25]. A large review, pri-
marily of adult patients, demonstrated that there is a
significantly enhanced risk of postoperative VTE that
seems to be related to glucocorticoid excess resulting in
modification of coagulation and fibrinolysis [22]. Unfor-
tunately, at this time, no clear consensus guidelines exist
for optimal prophylaxis regimens, especially in pediatrics
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sult of the hypercoagulable state recognized with Cush-
ing syndrome.
Our patient’s ultimate presentation was presumably
fulminant sepsis that was the result of several factors:
possible early clinical signs of illness that were not rec-
ognized in her home setting that delayed her presenta-
tion to the ED; her prolonged hypercortisolemia; her
likely being an immunocompromised host; uncertainity
regarding whether she received her stress dose of ste-
roids during her acute illness; and adrenal crisis, which is
a very frequent complication in the post-adrenalectomy
patient that can lead to premature death [26]. Studies have
shown that insufficient patient education can be contribu-
tory [27]. The increased risk of infection appears to be
present prior to treatment and may persist during long-
term follow-up [28]. Synthetic glucocorticoids are the most
commonly prescribed class of immunomodulatory medica-
tions, and supraphysiologic endogenous glucocorticoids
can cause a state of immunosuppression [29, 30]. Glucocor-
ticoids represent the endogenous mechanism to suppress
inflammatory gene response. Persistent hypercortisolism re-
sults in lymphopenia, both directly and indirectly [30]. The
immune system was fragile in our patient during times of
hypercortisolemia and continued to be so post-operatively.
Whether the immune system recovers, and if so, when, re-
mains unclear. Chemoprophylaxis with antibiotics might be
prudent, and guidelines for this management are greatly
needed.
Conclusions
This case highlights the numerous significant challenges,
both diagnostic and therapeutic, physicians face when
treating children with Cushing syndrome and its comor-
bidities [31, 32]. In addition, it describes the many gaps
that may exist in the provision of care for a patient with
this condition. These gaps need to be anticipated and
taken as seriously as taking the patient to surgery. Al-
though we are focusing on the operating procedure to
resolve the hypercortisolemia, we are far from achieving
resolution of the cormobidities, regardless of the success
of the adrenalectomy. Our patient underwent bilateral
adrenalectomy, however the consequences of hypercorti-
solism were not immediately reversed, similar to cases
reported in the literature, particularly for the short term.
The resolution of the source of hypercortisolemia does
not imply regression of hypertension or recovery of the
immune system [21, 28]. Instead, strategies must be de-
veloped to deal with both short- and long-term residual
manifestations of Cushing syndrome, such as cardiovas-
cular comorbidities and immunosuppression.
Our patient taught us several lessons. First and fore-
most is that the earlier the diagnosis, the less exposure
the patient has to steroids. Accordingly, as has beennoted previously, the constellation of clinical signs
(including obesity coupled with growth failure) must be
evaluated, rather than focusing exclusively on the obes-
ity. The second important lesson is that recognizing the
preparedness of the parents to deal with comorbidities
of their child’s Cushing syndrome is of paramount im-
portance. The parents’ failure to recognize signs of sepsis
combined with most likely lack of stress steroid coverage
may have placed our patient at risk for compromise of
her immune system and presumably contributed to
the decompensation secondary to sepsis. Development
of multidisciplinary team guidelines for postoperative
management of Cushing syndrome and recommenda-
tions for interventions regarding the immune system, as
well as on-going family education, would enhance the
physician’s success to complete the circle of manage-
ment challenges and stabilize the patient with Cushing
syndrome for the long term.
Consent for photography and use in a manuscript was
discussed and obtained from family.
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